Evidence map›Paper›PMID 27695884›Full record

ReviewIntensive care medicine2016

Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy.

Anders Perner, Anthony C Gordon, Daniel De Backer, George Dimopoulos, James A Russell, Jeffrey Lipman, Jens-Ulrik Jensen, John Myburgh, Mervyn Singer, Rinaldo Bellomo and 1 more

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Intensive care medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07270523 (Therapeutic Monitoring of Beta-lactams in Critically Ill Patients With Sepsis), which is not on this map. Cited by 104 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07270523 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Therapeutic Monitoring of Beta-lactams in Critically Ill Patients With Sepsis: OPTIBETA Clinical Trial Protocol

TypeinterventionalSponsorComplexo Hospitalario Universitario de A CoruñaRan2026 to 2029Enrolled198ConditionsBacterial SepsisArmsIndividualized dosing of beta-lactam antibiotics based on therapeutic monitoring
3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. IL-15/NKG2D signaling-mediated activation of CD8Journal of thoracic disease · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anders PernerDepartment of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. anders.perner@regionh.dk.
Anthony C GordonSection of Anaesthetics, Pain Medicine and Intensive Care, Department of Surgery and Cancer, Imperial College London, London, UK.
Daniel De BackerDepartment of Intensive Care, CHIREC Hospitals, Université Libre de Bruxelles, Brussels, Belgium.
George DimopoulosDepartment of Critical Care, University Hospital ATTIKON, Medical School, University of Athens, Athens, Greece.
James A RussellCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Jeffrey LipmanRoyal Brisbane and Women's Hospital, The University of Queensland, Brisbane, QLD, Australia.
Jens-Ulrik JensenCHIP and PERSIMUNE, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
John MyburghThe George Institute for Global Health, University of Sydney, Sydney, NSW, Australia.
Mervyn SingerDivision of Medicine, Bloomsbury Institute of Intensive Care Medicine, University College London, London, WC1E 6BT, UK.
Rinaldo BellomoSchool of Medicine, The University of Melbourne, Melbourne, VIC, Australia.
Timothy WalshAnaesthetics, Critical Care, and Pain Medicine, Edinburgh University, Edinburgh, Scotland, UK.

Funding

Department of Health PB-PG-0610-22350
6 · The paper itself

Abstract

Sepsis is a major growing global burden and a major challenge to intensive care clinicians, researchers, guideline committee members and policy makers, because of its high and increasing incidence and great pathophysiological, molecular, genetic and clinical complexity. In spite of recent progress, short-term mortality remains high and there is growing evidence of long-term morbidity and increased long-term mortality in survivors of sepsis both in developed and developing countries. Further improvement in the care of patients with sepsis will impact upon global health. In this narrative review, invited experts describe the expected challenges and progress to be made in the near future. We focus on diagnosis, resuscitation (fluids, vasopressors, inotropes, blood transfusion and hemodynamic targets) and infection (antibiotics and infection biomarkers), as these areas are key, if initial management and subsequent outcomes are to be improved in patients with sepsis.

Indexed as

ResuscitationAnti-Bacterial AgentsBiomarkersCardiotonic AgentsCritical CareFluid TherapyHemodynamicsHumansIncidenceIntensive Care UnitsSepsisVasoconstrictor AgentsAnti-Bacterial AgentsBiomarkersCardiotonic AgentsVasoconstrictor AgentsAntibioticCritical careIntensive careSepsisShock

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.